DNAJB8-AS1: A Potential Drug Target and Biomarker (G285224)

Target Name: DNAJB8-AS1

NCBI ID: G285224

DNAJB8-AS1

Other Name(s): DNAJB8 antisense RNA 1 | DNAJB8 antisense RNA 1 (non-protein coding)

DNAJB8-AS1: A Potential Drug Target and Biomarker

DNAJB8-AS1, a non-coding RNA (ncRNA), has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, function, and expression pattern make it an attractive candidate for further investigation. In this article, we will explore the biology of DNAJB8-AS1 and its potential as a drug target and biomarker.

Overview of DNAJB8-AS1

DNAJB8-AS1 is a non-coding RNA molecule that is located within the intron of the DNAJB8 gene. It has a length of 291 nucleotides and an estimated 19.3% enrichment at its most stable region. DNAJB8-AS1 is primarily expressed in the brain and nervous system, and its levels are highly correlated with the expression of the DNAJB8 gene.

DNAJB8-AS1 functions as an antisense RNA, meaning it matches the sequence of the DNAJB8 gene but is not a functional RNA. Its unique structure allows it to interact with the protein encoded by the DNAJB8 gene, thereby inhibiting its translation into protein and potentially leading to the degradation of the protein.

Potential Drug Target

The protein encoded by the DNAJB8 gene is involved in various cellular processes, including cell adhesion, migration, and survival. DNAJB8-AS1 has been shown to interact with the protein in a variety of cell lines, including cancer cells, neuroblastoma cells, and primary brain cortical cells. These interactions may contribute to the stabilization of the protein and potentially contribute to its expression levels.

Furthermore, DNAJB8-AS1 has been shown to be downregulated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that it may be a potential drug target for these diseases.

Biomarker Potential

DNAJB8-AS1 has also been identified as a potential biomarker for various diseases. Its expression levels are highly correlated with the expression of the DNAJB8 gene, which encodes a protein involved in cell adhesion and migration. This suggests that DNAJB8-AS1 may be a useful biomarker for tracking disease progression and evaluating the effectiveness of therapeutic interventions.

In addition, DNAJB8-AS1 has been shown to have potential utility as a diagnostic marker for various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its expression levels are also significantly reduced in these disorders, which may indicate that it could be a useful diagnostic tool for these conditions.

Conclusion

In conclusion, DNAJB8-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and function make it an attractive candidate for further investigation. Further studies are needed to determine its role in disease progression and its potential as a therapeutic intervention and diagnostic tool.

Protein Name: DNAJB8 Antisense RNA 1

The "DNAJB8-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJB8-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets